On February 27, Jiangsu Sinopep-Allsino Biopharmaceutical Co.Ltd(688076) released the performance express of 2021. During the reporting period, the company achieved an operating revenue of 641869500 yuan, an increase of 13.23% over the same period of last year; The operating profit was 1266087 million yuan, a decrease of 11.96% over the same period of last year; The net profit attributable to the owners of the parent company was 114166 million yuan, a decrease of 7.51% over the same period of last year; The net profit attributable to the owner of the parent company after deducting non recurring profits and losses was 1037941 million yuan, an increase of 9.87% over the same period of last year.
Jiangsu Sinopep-Allsino Biopharmaceutical Co.Ltd(688076) said that during the reporting period, the company consolidated its development foundation, strengthened capacity-building, carried out all businesses in a normal and orderly manner, and its operating revenue increased by 13.23% over the same period of last year. The company strengthened BD construction, deepened the cooperative relationship with overseas customers, actively expanded Chinese customers, and the revenue of customized products and services increased steadily.
The announcement shows that the company’s net profit attributable to shareholders of listed companies decreased by 7.51% compared with 2020 Jiangsu Sinopep-Allsino Biopharmaceutical Co.Ltd(688076) said that the company has strengthened capacity-building, some production capacity is still in the process of gradually reaching production and increasing efficiency, and the cost level of the company has increased; In addition, the company’s customized products and services are affected by the sales of end products of downstream customers, the progress of R & D registration and approval, delivery and other factors, resulting in revenue fluctuations and a decline in net profit; Meanwhile, non recurring gains and losses such as government subsidies decreased compared with 2020. Wu Wenfeng
